Blocked by regulations… Gene analysis market growth in blocked way
Kim Ji Seob | cloud50@ | 2017-12-13 11:13:11
Consumers have been able to receive gene analysis services directly without going through medical institutions since July last year. However, the domestic market is hardly activated.
According to the gene analysis industry on December 12, various companies launched `Direct Consumer Directed Genetics (DTC)` service since last year. A variety of gene analysis companies are actively working with pharmacy chains, health food companies, and insurance companies.
Meanwhile, only a limited number of genetic tests were allowed, and companies were found to be unable to provide a variety of services, leading to sales. Macrogen, for example, co-invested with LG Household & Health Care last October to launch a joint venture called "Mizen Story," but sales are not yet visible. Another DTC service provider said, "It is difficult to find sales yet."
According to the Bioethics Act, 12 kinds of genetic analysis items that consumers can receive are caffeine metabolism, blood pressure, blood sugar, pigmentation, hair thickness and hair loss. In developed countries, however, there are no such laws and regulations or the scope of inspection is freed.
The United States only allowed DTCs for 10 diseases in April, including Alzheimer`s and Parkinson`s, in the Food and Drug Administration (FDA). Japan and the United Kingdom are not regulated by law, and they cease to be recommendations from the guidelines or the association. In the United States, Japan and the United Kingdom, chronic disease prediction tests and hereditary disease burden tests can be performed. Since 2008, the United States has launched DTC services online, and more than 100 genetic analysis services have been launched in 23 US and Pathway Genomics. In Japan, companies such as Yahoo offer more than 300 kinds of services. It is alive.
According to research firm Credit Research, global DTC market is expected to increase by 25% annually from KRW 80 billion in 2015 to KRW 400 billion by 2022. However, in the domestic market, only 12 limited services are provided, so it is not possible to provide services at the level of developed countries. As a result, genetic analysis companies are concentrating on selling products for beauty and healthcare through currently available gene analysis information, and there is a concern that the market may be focused on product sales rather than genetic analysis and disease prevention.
"It is difficult to open the market because disease prediction and genetic diseases are not allowed for genetic analysis services," an industry expert said. "We need to expand the scope of genetic testing and alleviate regulations so that consumers can get the information they need directly from the company. The precision medical industry can grow rapidly. "
By Kim Ji Seob cloud50@
[ copyright ⓒ The Digitaltimes ]
According to the gene analysis industry on December 12, various companies launched `Direct Consumer Directed Genetics (DTC)` service since last year. A variety of gene analysis companies are actively working with pharmacy chains, health food companies, and insurance companies.
Meanwhile, only a limited number of genetic tests were allowed, and companies were found to be unable to provide a variety of services, leading to sales. Macrogen, for example, co-invested with LG Household & Health Care last October to launch a joint venture called "Mizen Story," but sales are not yet visible. Another DTC service provider said, "It is difficult to find sales yet."
According to the Bioethics Act, 12 kinds of genetic analysis items that consumers can receive are caffeine metabolism, blood pressure, blood sugar, pigmentation, hair thickness and hair loss. In developed countries, however, there are no such laws and regulations or the scope of inspection is freed.
The United States only allowed DTCs for 10 diseases in April, including Alzheimer`s and Parkinson`s, in the Food and Drug Administration (FDA). Japan and the United Kingdom are not regulated by law, and they cease to be recommendations from the guidelines or the association. In the United States, Japan and the United Kingdom, chronic disease prediction tests and hereditary disease burden tests can be performed. Since 2008, the United States has launched DTC services online, and more than 100 genetic analysis services have been launched in 23 US and Pathway Genomics. In Japan, companies such as Yahoo offer more than 300 kinds of services. It is alive.
According to research firm Credit Research, global DTC market is expected to increase by 25% annually from KRW 80 billion in 2015 to KRW 400 billion by 2022. However, in the domestic market, only 12 limited services are provided, so it is not possible to provide services at the level of developed countries. As a result, genetic analysis companies are concentrating on selling products for beauty and healthcare through currently available gene analysis information, and there is a concern that the market may be focused on product sales rather than genetic analysis and disease prevention.
"It is difficult to open the market because disease prediction and genetic diseases are not allowed for genetic analysis services," an industry expert said. "We need to expand the scope of genetic testing and alleviate regulations so that consumers can get the information they need directly from the company. The precision medical industry can grow rapidly. "
By Kim Ji Seob cloud50@